Abbott at Decade Low P/E: Bullish Supercycle Thesis vs. Cautious Integration Reality

What happened

Abbott Laboratories trades at a decade-low 17.7x forward earnings, yet the DeepValue master report maintains a WAIT rating due to the overhang from the $20.6B Exact Sciences acquisition. While the Seeking Alpha article highlights three underappreciated catalysts—Exact Sciences synergy, CMS CGM expansion, and Nutrition margin recovery—the latest 10-Q reveals a $679M YoY SG&A spike and Diagnostics weakness, with Rapid & Molecular falling 9.6% ex-FX. Medical Devices remains strong with 8.1% ex-FX growth and CGM sales reaching $2.0B, but the integration costs and guided dilution through 2027 temper near-term earnings power. The bull case hinges on CMS expanding Type 2 non-insulin CGM coverage, which management says is not in 2026 guidance, and on visible SG&A normalization. Until these proof points materialize in upcoming quarters, the risk/reward favors waiting rather than buying into the supercycle narrative.

Implication

For long-term investors, the stock offers asymmetric upside if the three catalysts materialize, but the timeline is uncertain and near-term dilution from Exact Sciences is real. The key checkpoints are sequential SG&A reduction from $3.7B in 1Q26, CGM growth acceleration above 7.6% ex-FX, and diagnostics stabilizing. If CMS moves on CGM coverage and Cancer Diagnostics scales, the stock could re-rate to $110 in a bull case; otherwise, persistent cost drags could push it to $75. The master report suggests trimming above $105 and finding attractive entry near $85, implying material downside risk from current $91.33. Given the 3.5 conviction rating and 3-6 month reassessment window, the prudent action is to wait for 2H26 proof points before committing capital.

Thesis delta

The Seeking Alpha article's bullish supercycle thesis is a plausible upside scenario, but the operating data from the latest filing shows integration costs and diagnostics softness that contradict a near-term re-rating. The shift is from 'mispriced opportunity' to 'show-me story' where the stock will only move higher if clear evidence of CGM acceleration and SG&A normalization emerges. The master report's WAIT rating is more grounded in current fundamentals, and the market's decade-low P/E is a reflection of tangible risks, not just pessimism.